Vectus Biosystems

Vectus Biosystems CapEx/OCF

CapEx to Operating Cash Flow Ratio of Vectus Biosystems (VBS.AX) as of Nov 5, 2026.

CapEx/OCF

-0.00

YoY

261.92%

Last updated:

CapEx to Operating Cash Flow Ratio of Vectus Biosystems is 2026 -0.00 . CapEx to Operating Cash Flow Ratio of Vectus Biosystems was 2025 -0.00 . It decreases by 261.92% lower compared to the previous year.

The Vectus Biosystems CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2019
-2.02 AUD
Jan 1, 2020
-0.70 AUD
Jan 1, 2021
-0.00 AUD
Jan 1, 2022
-0.47 AUD
Jan 1, 2023
-0.73 AUD
Jan 1, 2024
-3.34 AUD
Jan 1, 2025
-0.00 AUD
Jan 1, 2026
-0.00 AUD
The Vectus Biosystems CapEx/OCF history
YEARCapEx/OCFYoY
-0.00+261.92%
-0.00-99.99%
-3.34 %+358.85%
-0.73 %+53.95%
-0.47 %+769,575.93%
-0.00-99.99%
-0.70 %-65.33%
-2.02 %—
0.00-100.00%
-1.01 %-67.88%
-3.14 %+448.25%
-0.57 %-78.73%
-2.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectus Biosystems Stock analysis

What does Vectus Biosystems do? Vectus Biosystems Ltd. generates revenue through the development and commercialization of pharmaceutical products targeting fibrotic diseases and hypertension. The company focuses on VB0004, a compound designed to treat tissue hardening and high blood pressure, alongside candidates for fibrotic liver conditions like NASH and pulmonary fibrosis. Its subsidiary Accugen Pty Limited offers the Accugen platform, which provides qPCR reagents and software for accurate DNA and RNA quantification in laboratory testing. The primary buyers of these products are pharmaceutical companies and research institutions seeking advanced drug development tools and therapies for fibrotic disorders. Vectus Biosystems targets the medical research and development sector, specifically addressing unmet needs in fibrotic disease treatment. The Accugen platform serves laboratories requiring efficient molecular analysis tools, with its technology enhancing the speed and precision of qPCR testing. The company’s revenue streams are derived from both therapeutic product development and the sale of diagnostic solutions to biotech firms and academic research entities. The firm’s focus on fibrosis-related treatments, including heart, kidney, and liver diseases, positions it within niche therapeutic segments. Accugen’s reagents and software are sold to laboratories as part of the qPCR workflow, supporting drug discovery processes. Pharmaceutical companies and research organizations are the key segments purchasing Vectus Biosystems’ products for their R&D pipelines and clinical applications. Vectus Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectus Biosystems stock

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Vectus Biosystems since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Vectus Biosystems with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Vectus Biosystems

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Vectus Biosystems